<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="gastroenterology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">86</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2022.2907 </article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Gastroenterology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Characteristics, Evaluation, Treatment, and Prognosis of Cryptogenic Cirrhosis
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ghamdi</surname>
<given-names>Khalid Al</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bawareth</surname>
<given-names>Rozana</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alqufayi</surname>
<given-names>Abdulkarim</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshamase</surname>
<given-names>Raqhda</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Algarni</surname>
<given-names>Mohammad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshehri</surname>
<given-names>Abdulaziz</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshahrani</surname>
<given-names>Nawaf</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alatawi</surname>
<given-names>Jamayel</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allahiani</surname>
<given-names>Waleed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alhadlaq</surname>
<given-names>Faisal</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alabdullatif</surname>
<given-names>Ghaith</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alharbi</surname>
<given-names>Rawan</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>28</day>
<month>09</month>
<year>2022</year>
</pub-date>
<volume>2</volume>
<issue>9</issue>
<fpage>252</fpage>
<lpage>258</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>The term cryptogenic cirrhosis (CC) implies that the underlying etiology is uncertain and devoid of definitive clinical, serological, and histological criteria for a specific type of cirrhosis. CC denotes a spectrum of underlying causes, among whom, the majority of evidence implicates non-alcoholic steatohepatitis (NASH) led progression as the most frequent route. CC is held accountable for around 5% of cirrhosis cases today. Cirrhosis complications like liver failure and hepatocellular carcinoma appear as the first presenting feature of the disease, as in other hepatic diseases. The hepatocarcinogenic risk of CC is substantial, with hepatocellular carcinoma’s reported annual cumulative incidence ranging between 2.6% to 3.5%. The diagnosis of CC relies on the exclusion of distinctly recognizable diseases and involves a careful clinical assessment including risk history and family history, followed by laboratory testing including serology, autoantibodies, immunoglobulin concentrations, biomarkers for Wilson’s disease and Celiac disease, and lastly histological assessment for the prominent type and inflammation distribution, and typical presenting features of cirrhotic tissues. The definitive treatment of CC involves transplantation. In cases suspected to be linked with NASH, medical management until transplantation can be beneficial to the patient. The management of CC involves collaboration of primary care with gastroenterology, hepatology, and transplant consultation, and nutritional counseling. Data regarding survival post-transplantation is limited and has shown conflicting results.
</p>
</abstract>
<kwd-group>
<kwd>cryptogenic cirrhosis</kwd>
<kwd> non-alcoholic steatohepatitis</kwd>
<kwd> orthotropic liver transplantation</kwd>
</kwd-group>
</article-meta>
</front>
</article>